Heterogeneous Movement Disorders in Patients With C9orf72 Hexanucleotide Expansions
In this retrospective review, study researchers sought to assess the presentation of movement disorders in carriers of C9orf72 hexanucleotide repeat expansions.
In this retrospective review, study researchers sought to assess the presentation of movement disorders in carriers of C9orf72 hexanucleotide repeat expansions.
The transition from the International Classification of Disease (ICD)-9 to ICD-10 coding system may impact estimates of neurologic disease prevalence.
With cannabis in the United States becoming more widely available for medical and recreational use, some with Parkinson disease (PD) are trying cannabis to control symptoms. However, not that much is currently known about the attitudes and experiences regarding cannabis use among those with PD.
With no conclusive preclinical diagnostic test for Parkinson disease, diagnosis is achieved primarily through observations by a physician of the decline in motor functions. And while studies of sebum are commonplace in dermatological conditions, sebum as a biofluid has rarely been used in disease diagnostics.
Increased levels of physical activity may have a protective effect on apolipoprotein E ε4-related cognitive decline in early PD.
Type 2 diabetes mellitus is associated with an increased risk for Parkinson disease (PD), as well as more rapid PD progression.
A team of researchers investigated the longitudinal association between high HDL-C levels, HDL-C variability, and the risk of developing Parkinson disease.
Users of terazosin, doxazosin, or alfuzosin are at lower risk for developing Parkinson disease compared with users of tamsulosin.
Among the non-motor symptoms of Parkinson’s disease, chronic pain has become a topic of increasing relevance in research and clinical settings.
The MM4PD ambulatory monitoring system can facilitate continuous symptom monitoring through a smartwatch.